Patient characteristics and outcome of the 12 patients included into the trial.

Abbreviations: ASXL1, additional sex combs like 1; AZA, 5-azacitidine; BM, bone marrow; CR, complete remission; FLT3, fms-like tyrosine kinase 3; IDH, isocitrate dehydrogenase; ITD, internal tandem duplication; NPM1, Nucleophosmin 1; PS, ECOG performance status; TET2, ten-eleven translocation 2.
aPresence of a sole trisomy in each of two clones.
bMutational analysis revealed wildtype status for NPM and no FLT3-ITD. Analysis of ASXL1, DNMT3A, IDH1, IDH2 and TET2 could not be performed due to lack of material.
cIn patient 10, CR was achieved after trial termination without further therapy.
dRelapse after achievement of CR by salvage therapy.